Percheron Therapeutics continues to advance Duchenne treatment
Melbourne, Victoria
|
March 07, 2024 10:40 AM Eastern Standard Time
Percheron Therapeutics Ltd (ASX:PER) managing director and CEO James Garner sits down with Proactive’s Jonathan Jackson for a comprehensive update of the company and its focus on treating rare diseases, including the advancement of its lead program, ATL1102. Percheron is dedicated to developing therapies for conditions with high unmet medical needs, particularly emphasising its efforts on Duchenne Muscular Dystrophy (DMD), a rare and severe muscle-wasting disease.
Garner provides an update on ATL1102, highlighting its promising progress in clinical development and the commercial opportunity presented by the need for effective DMD treatments. Percheron is well-funded for its upcoming initiatives, with a strong focus on advancing its pipeline towards market readiness.
Garner also outlines the company’s strategic path to market, which includes ongoing development work and the exploration of partnership opportunities to enhance ATL1102’s commercial viability and accessibility.
The company’s participation in the Annual Clinical and Scientific Conference of the Muscular Dystrophy Association was marked by three poster presentations. Garner highlighted the importance of this involvement, detailing the significant findings presented and their relevance to the broader scientific and medical community’s understanding of DMD and potential treatments.
Finally, he outlines the investment case for Percheron, emphasising the company’s unique position in addressing rare diseases with significant unmet needs.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
